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An in vivo screen was performed in search of chem-
icals capable of enhancing neuron formation in the
hippocampus of adult mice. Eight of 1000 small
molecules tested enhanced neuron formation in the
subgranular zone of the dentate gyrus. Among these
was an aminopropyl carbazole, designated P7C3,
endowedwith favorable pharmacological properties.
In vivo studies gave evidence that P7C3 exerts its
proneurogenic activity by protecting newborn
neurons from apoptosis. Mice missing the gene en-
coding neuronal PAS domain protein 3 (NPAS3) are
devoid of hippocampal neurogenesis and display
malformation and electrophysiological dysfunction
of the dentate gyrus. Prolonged administration of
P7C3 to npas3/ mice corrected these deficits by
normalizing levels of apoptosis of newborn hippo-
campal neurons. Prolonged administration of P7C3
to aged rats also enhanced neurogenesis in the den-
tate gyrus, impeded neuron death, and preserved
cognitive capacity as a function of terminal aging.INTRODUCTION
Inspirational work led by Fernando Nottebohm has proven that
the adult vertebrate brain fosters the birth and functional incor-
poration of newly formed neurons (Paton and Nottebohm,
1984). Nottebohm’s studies on neuron birth as a prerequisite
for avian song learning validated earlier claims of adult neuro-
genesis by Joseph Altman in the 1960s. Altman challenged the
prevailing neuroscience dogma that no new neurons could be
added to the adult mammalian brain when he reported autora-
diographic evidence of new neuron formation in the hippo-
campal dentate gyrus, olfactory bulb, and cerebral cortex of
adult rats (Altman, 1962; Altman and Das, 1965). It is now
accepted that all mammalian species, including humans, harborreservoirs of neuronal stem cells in the subgranular zone (SGZ) of
the hippocampal dentate gyrus and the subventricular zone
(SVZ) (Gross, 2000). Neural stem cells in the SVZ facilitate
formation of new neurons that migrate rostrally to the olfactory
bulb. Neural stem cells in the SGZ produce neurons that inte-
grate locally in the granular layer of the dentate gyrus, a region
of the hippocampus that exhibits lifelong structural and func-
tional plasticity.
New neuron formation in the adult mouse brain is influenced
by environmental, chemical, and genetic variables, such as envi-
ronmental enrichment (Kempermann et al., 1997) or voluntary
exercise (van Praag et al., 1999). Administration of antidepres-
sant drugs to rodents and humans has also been reported to
enhance adult neurogenesis (Schmidt and Duman, 2007;
Boldrini et al., 2009). Among many genes reported to impact
adult neurogenesis is the gene encoding NPAS3, a central
nervous system-specific transcription factor that is associated
with learning disability and mental illness (Kamnasaran et al.,
2003; Pickard et al., 2005, 2006, 2009; Macintyre et al., 2010).
Npas3/ mice display behavioral abnormalities (Erbel-Sieler
et al., 2004) and a profound loss of adult hippocampal neurogen-
esis (Pieper et al., 2005). As will be shown, npas3/ mice also
display dentate granular cell dysmorphologies and aberrations
in synaptic transmission. Here, we report the results of an
in vivo screen for small molecules capable of restoring hippo-
campal neurogenesis to npas3/ mice.RESULTS
Computational methods were employed to select 1000
compounds from a library of 200,000 drug-like chemicals with
consideration of chemical diversity, complexity, and potential
toxicity. Compounds were randomly pooled into groups of
ten and administered by intracerebroventricular (ICV) injection
at a constant rate over 7 days into the left lateral ventricle of
living mice via osmotic minipumps. Compounds were adminis-
tered at a concentration of 10 mM each, making total solute
concentration 100 mM. Although it is difficult to predict the final
brain concentration of each compound over the 7 day infusionCell 142, 39–51, July 9, 2010 ª2010 Elsevier Inc. 39
period, we designed our screen with a logical consideration of
this variable. At 10 mM concentration, it is reasonable to esti-
mate that compounds were administered at low-micromolar
to mid-nanomolar concentrations (Extended Experimental
Procedures).
During compound infusion, animals received intraperitoneal
(IP) injection daily with the thymidine analog bromodeoxyuridine
(BrdU, 50 mg/kg) to score birth and survival of proliferating
hippocampal neural precursor cells. Because social interaction
and voluntary exercise stimulate hippocampal neurogenesis,
mice were housed individually without access to running wheels
starting 1 week prior to screening in order to ensure a low
baseline level of neurogenesis. After 1 week of compound
administration, BrdU immunohistochemistry was used to quan-
tify neurogenesis in the SGZ of the brain hemisphere contralat-
eral to the side of infusion. Every fifth section throughout the
rostral-caudal extent of the hippocampus was analyzed, and
the number of BrdU+ cells was normalized against the volume
of the dentate gyrus.
Because we considered both increased proliferation and
survival of newborn neurons to be important screening parame-
ters, we conducted our screen over 7 days in order to detect
molecules that might augment either process. This was based
on pulse-chase experiments with a single injection of BrdU, under
identical conditions to our screen, which revealed that 40% of
newborn cells in the SGZ die within the first 5 days after their birth
(Figure S1A available online). ICV infusions of either fibroblast
growth factor 2 (FGF-2) or artificial cerebral spinal fluid (aCSF)
were employed as positive and negative controls. There was no
difference in the number of BrdU+ cells in the SGZ between
mice subjected to surgical pump implantation and infusion with
aCSF and micehavinghad nosurgery (FigureS1B). Thisconfirmed
the validity of our in vivo approach to assess the ability of ICV-
infused compounds to enhance hippocampal neurogenesis in
the brain hemisphere contralateral to that of compound infusion.
We reasoned that it was important that neurogenesis triggered
by any compound be localized to the exact region of the brain
known to produce new neurons at an enhanced level in response
to healthy conditions such as wheel running, environmental
enrichment, or social interaction. We thus focused solely on
compound pools that stimulated BrdU incorporation in the
SGZ of the dentate gyrus (Figure S1C).
Each pool was tested on two mice, and ten pools were found
to enhance dentate gyrus-specific neurogenesis as much as
FGF-2 (Figure 1A). Each pool that scored positive was re-evalu-
ated in two additional mice and verified to exert a proneurogenic
effect with statistical significance (Figure S1D). In order to iden-
tify single, proneurogenic compounds, we broke down positive
pools into their component molecules, each of which was
infused individually at two concentrations (10 mM and 100 mM)
in two mice per concentration. Figure 1B shows the results of
breakdown assays on pool #7, wherein it was discovered that
neurogenesis was selectively stimulated by one of the constit-
uent chemicals of the pool (compound #3), with the remaining
chemicals in the pool demonstrating no effect. We have desig-
nated this compound as P7C3 (pool #7, compound #3).
Of the ten positive pools, eight yielded a single proneurogenic
compound (Table S1). Pools 14 and 69 failed to reveal activity in40 Cell 142, 39–51, July 9, 2010 ª2010 Elsevier Inc.a single species. The activity of these pools may have been arti-
factually spurious or may have been generated by the combined
activity of two or more compounds. We considered both
scenarios sufficiently problematic such that we disregarded
these pools and focused exclusively on individually efficacious
molecules. To ensure validity of the eight individually efficacious
molecules, we obtained fresh compounds from the original
manufacturer, confirmed purity and molecular weight by liquid
chromatography-mass spectrometry (LC-MS), and then as-
sayed each one at 10 mM in three additional mice. All eight resup-
plied compounds demonstrated SGZ-specific proneurogenic
activity (Figure S1E).
Among the eight proneurogenic compounds, in silico predic-
tion of absorption, distribution, metabolism, and excretion
(ADME) characteristics suggested that P7C3 held the highest
potential for favorable pharmacological properties. Fortuitously,
P7C3 could be formulated for intravenous (IV), oral, and IP
delivery, allowing determination of half-life, rate of clearance,
bioavailability, and blood brain barrier penetration. Noncompart-
mental pharmacokinetic analysis of P7C3 in plasma and whole-
brain tissue was undertaken after single IV, IP, and oral gavage
administrations. P7C3 was 32% orally bioavailable, readily
able to cross the blood-brain barrier (AUC brain: AUC plasma
ratio of 3.7 for oral delivery), and endowed with a plasma terminal
half life of 6.7 hr after IP delivery. These favorable properties
facilitated a dose-response experiment wherein daily oral
administration of P7C3 for 7 days to adult mice was monitored
for brain levels of the chemical and proneurogenic efficacy
(Figure 1C). Maximal, proneurogenic efficacy was observed at
oral doses of 5 mg/kg and above, and graded reductions in
efficacy were observed at doses of 2.5 and 1 mg/kg. LC-MS
analysis of brain levels of P7C3 in the dose ranges of 1 and
2.5 mg/kg revealed corresponding compound concentrations
of 213 nM (101 ng/g brain tissue) and 1.13 mM (534 ng/g brain
tissue) 5 hr after dosing.
Functional Studies of Chemical Variants of P7C3
To further evaluate the properties of P7C3, we conducted an
in vivo structure activity relationship (SAR) study using 37 chem-
ical derivatives of the compound for assessment of proneuro-
genic activity as performed in the original screen (Figure 2A).
One variant showed activity enhancement, while roughly 15%
retained proneurogenic activity indistinguishable from the parent
compound. A handful of compounds yielded partially diminished
activity, and the majority were inactive.
The single derivative of P7C3 exhibiting enhanced activity
(P7C3A20) replaced the hydroxyl group at the chiral center of
the linker with fluorine. Two other variants that have been em-
ployed as controls in later experiments were inactive. One of
these (P7C3A29) replaced the aniline moiety with a pyrazole.
The other (P7C3A35) lengthened the linker connecting the tricy-
clic carbazole to the aniline ring by a CH2 unit (Figure 2B).
Among compounds retaining activity equivalent to the parent
molecule was a variant (P7C3-OMe) in which the aniline ring of
P7C3 was substituted by an anisidine. This variant lent itself
to preparation of R- and S-enantiomers around its single chiral
center (Figure 2B). The two enantiomers of P7C3-OMe
were synthesized, separated, and evaluated in the in vivo
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Figure 1. In Vivo Screen for Proneurogenic
Molecules
(A) The total number of BrdU+ cells in the SGZ
doubled after 7 day infusion with FGF-2 relative
to vehicle. Each pool of ten compounds was
tested for proneurogenic efficacy in two mice,
and ten pools displayed efficacy comparable to
FGF-2 infusion. The majority of pools displayed
no effect.
(B) In vivo evaluation in four mice each of the ten
individual compounds in pool #7 revealed exclu-
sive activity for compound #3. Immunohisto-
chemically visualized BrdU incorporation in the
SGZ is notably greater in animals infused with
either pool #7 or compound #3 from pool #7 rela-
tive to vehicle-infused animals. All micrographs
were taken at the same magnification. (The scale
bar represents 200 mm.)
(C) P7C3 concentration in mouse brain tissue
correlated with oral dosing. Proneurogenic effi-
cacy of P7C3 was roughly double that of vehicle
at doses ranging from 5 to 40 mg/kg. At
decreasing dosage of P7C3 the amount of neuro-
genesis decreased accordingly, until reaching
levels no greater than vehicle at compound doses
below 1.0 mg/kg.
In all graphs, data are expressed as mean ± stan-
dard error of the mean (SEM). See also Figure S1
and Table S1.neurogenesis assay, and the R-enantiomer was noted to retain
the vast majority of proneurogenic activity. Figure 2B shows
the results of dose-response studies wherein the activity of the
parent compound (P7C3) was compared with the activities of
the hydroxyl-to-fluorine variant (P7C3A20), the two enantiomers
of P7C3-OMe, and the two inactive variants (P7C3A29 and
P7C3A35). These dose-response assays confirmed that (1)
P7C3A20 is superior in proneurogenic efficacy to the parent
compound, (2) theR-enantiomer of P7C3-OMe is far more active
than the S-enantiomer, and (3) P7C3A29 and P7C3A35 are
inactive.
P7C3 Enhances Survival of Newborn Neurons
Access to P7C3, an easily administered proneurogenic
compound, allowed prosecution of two questions. First, what
sorts of cells are produced after P7C3 enhances BrdU incorpo-
ration in the SGZ? Second, is P7C3-mediated enhancement ofCell 142,neurogenesis attributable to increased
levels of cell proliferation? Or, instead,
might it be that P7C3 enhances neuro-
genesis by protecting newborn neurons
from cell death during the month-long
differentiation pathway taken between
their birth and eventual incorporation
into the dentate gyrus granular layer as
properly wired neurons?
To address the first question, we
stained brain tissue from animals
exposed to orally administered P7C3 for
30 days for doublecortin (DCX), a microtu-bule-associated protein that serves as a marker of neurogenesis
by virtue of transient expression in newly formed neurons
between the timing of their birth and final maturation (Brown
et al., 2003). As shown in Figure 3A, the relative abundance of
DCX+ neurons increased dramatically with prolonged adminis-
tration of P7C3. Prolonged exposure of mice to P7C3 further re-
sulted in generation of BrdU+ cells coexpressing the NeuN and
Prox1 markers of mature neurons (Figure S2A). By contrast, pro-
longed P7C3 administration did not affect the abundance of
hippocampal astrocytes or oligodendrocytes (Figure S2B). In
combination, these immunohistochemical assays confirm the
fact that P7C3 enhances neuron formation in the hippocampus
of adult mice.
The second question was addressed by comparing the ability
of P7C3 to enhance either short- or long-term incorporation of
BrdU in the dentate gyrus. Animals exposed to orally delivered
P7C3 or vehicle were administered a single pulse of BrdU39–51, July 9, 2010 ª2010 Elsevier Inc. 41
#B
rd
U
+C
el
ls
(1
E-
06
) /
 m
m
3 
D
en
ta
te
 G
yr
us
10     1    0.1
P7C3A20 (µM) P7C3A29 (µM) P7C3A35 (µM)
B
A
#B
rd
U
+C
el
ls
(1
E-
06
) /
 m
m
3 
D
en
ta
te
 G
yr
us
P7C3 (R)-P7C3-OMe (S)-P7C3-OMe
P7C3A20 P7C3A29 P7C3A35
10     1    0.1 10     1    0.1 10     1    0.1 10     1    0.1 10     1    0.1
(S)-P7C3-Ome (µM)(R)- P7C3-Ome (µM)P7C3 (µM)
Figure 2. SAR Analysis of Structural Variants of P7C3
(A) An in vivo SAR study with 37 analogs of P7C3 showed that some analogs
had proneurogenic activity comparable to the parent compound, whereas
others had either no activity or activity intermediate between vehicle and
FGF controls. A single compound (P7C3A20) showed enhanced efficacy.
(B) Comparison of proneurogenic efficacy of analogs of P7C3 showed that the
(R)-enantiomer of P7C3-OMe was active, whereas the (S)-enantiomer was not.
P7C3A20 exhibited enhanced activity, while P7C3A29 and P7C3A35 suffered
structural changes that abolished activity.
In all graphs, data are expressed as mean ± SEM.(150 mg/kg) via IP injection. Short-term effects on neuron birth
were monitored by sacrifice of animals 1 hr after BrdU injection
after P7C3 had been administered for 7 days, followed by immu-
nohistochemical detection of BrdU in the SGZ. P7C3 administra-
tion did not elevate the level of BrdU+ cells relative to vehicle in
this short-term assay (Figure 3B). At the 1 day after BrdU admin-
istration time point, both groups still showed no statistically
significant differences in the number of BrdU+ cells. By the
5 day time point, at which time 40% of cells born by day 1 nor-
mally die (Figure S1A), animals that received P7C3 showed42 Cell 142, 39–51, July 9, 2010 ª2010 Elsevier Inc.a statistically significant, 25% increase in BrdU+ cells compared
to the vehicle group. This difference progressed with time such
that mice that received a daily oral dose of P7C3 for 30 days after
the BrdU pulse exhibited a 500% increase in abundance of
BrdU+ cells in the dentate gyrus relative to vehicle controls
(Figure 3B).
In this longer-term trial, BrdU+ cells were observed both within
the SGZ and the granular layer (Figure 3B). We hypothesize that
the latter, BrdU+ cells represent mature neurons that have func-
tionally incorporated into the dentate gyrus. Observations
supportive of this interpretation will be presented in a subsequent
section of this report. In summary, these experiments show that
P7C3 enhances the formation of neurons in the mature hippo-
campus and that its mode of action takes place subsequent to
the initiation of neural precursor cell proliferation.
P7C3 Corrects Deficits in the Dentate Gyrus
of npas3/ Mice
Npas3/ mice suffer a clear-cut impairment in adult neurogen-
esis (Pieper et al., 2005). By evaluating BrdU incorporation in the
short-term assay 1 hr after BrdU pulse, it was observed that
npas3/ mice have no deficit in the initial proliferation of neural
precursor cells in the SGZ (Figure S3A). This is in contrast to our
earlier observations of profoundly diminished BrdU labeling in
the dentate gyrus of npas3/ mice when BrdU was adminis-
tered for a longer period of time (12 days) (Pieper et al., 2005).
Knowing that NPAS3 is required for proper expression of fibro-
blast growth factor receptor 1 in the hippocampus (Pieper
et al., 2005), it is possible that impediments in growth factor
signaling might impair the trophic environment critical for survival
of newborn neurons in the dentate gyrus. To test this idea, we
compared brain tissue from npas3/ mice with that of wild-
type littermates for the presence of cleaved caspase 3
(CCSP3)-positive (apoptotic) cells in the SGZ. A statistically
significant, 3-fold increase in CCSP3-positive cells was
observed in the dentate gyrus of npas3/ mice (Figure S3A).
This enhanced level of apoptosis is likely to account, at least in
part, for the nearly complete elimination of adult neurogenesis
in npas3/ mice.
In addition to a deficit in adult neurogenesis, npas3/ mice
display abnormalities in both the morphology and electrophysi-
ology of dentate gyrus granular neurons. Relative to wild-type
animals, Golgi-Cox staining revealed severe attenuation in
dendritic branching and spine density of npas3/ dentate gyrus
granular neurons (Figure 4A). Significant genotype-specific defi-
cits were also observed by comparing electrophysiologic record-
ings of excitatory postsynaptic potentials (fEPSP) of npas3/
mice with wild-type littermates (Figure 4B). Such studies revealed
aberrant hyperexcitability of synaptic transmission in npas3/
mice both in the outer molecular layer of the dentate gyrus and
in the CA1 region of the hippocampus (Figure 4B).
Armed with these genotype- and region-specific deficits in
neuron morphology and electrophysiological activity, we set
out to test whether prolonged administration of P7C3 might
repair either or both deficits in npas3/ mice. We first verified
that P7C3 was capable of enhancing hippocampal neurogenesis
in npas3/ mice (Figure S3B). Knowing that formation of the
dentate gyrus initiates in the mouse embryo around embryonic
H
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Figure 3. P7C3 Treatment Enhances
Production and Survival of Neural Precursor
Cells Destined to a Neuronal Fate
(A) Immunohistochemical staining for DCX was
increased in newborn neurons in mice that were
administered P7C3.
(B) P7C3 enhances hippocampal neurogenesis by
promoting survival of newborn neurons without
affecting proliferation.
In both (A) and (B), both sets of micrographs were
taken at the same magnification (scale bars repre-
sent 50 mm) and are representative of ten sections
from each of five mice in each group. Data are
expressed as mean ± SEM. See also Figure S2.day 14 (Stanfield and Cowan, 1988), we sought to expose
animals to P7C3 for as extended a period of time as possible
in order to give the compound the best possible chance for
success. After oral gavage of pregnant female mice, day 14
embryos were recovered, dissected, and processed by acetoni-
trile:water extraction so that P7C3 levels could be measured in
the embryonic brain. Daily administration of 20 mg/kg of P7C3
to pregnant females yielded appreciable levels of the compound
in the brain tissue of developing embryos. It was similarly
observed that oral administration of the compound to lactating
females led to delivery of P7C3 to the brain tissue of weanling
pups. In both cases, LC-MS-based quantitation of P7C3 re-
vealed levels of compound accumulation at or above the
1.35 mM limit required to support adult neurogenesis (Figure 1C).
Finally, it was observed that daily IP administration of P7C3 to
weaned pups at 20 mg/kg yielded brain levels of P7C3 at or
above the level required to enhance adult neurogenesis.
Female mice heterozygous at the NPAS3 locus were mated
to heterozygous males. Two weeks after mating, females
were given a daily oral gavage of either 20 mg/kg of P7C3 or
vehicle. Dosing was continued throughout the last trimester ofCell 142,pregnancy, as well as the 3 week post-
natal period of lactation. After weaning,
pups were given a daily IP dose of either
20 mg/kg P7C3 or vehicle. At about 7
weeks of age, mice were switched to
oral gavage of the same dose of P7C3 or
vehicle. When mice were 3 months of
age, they were sacrificed, and brain tissue
was subjected to either Golgi-Cox stain-
ing or electrophysiological recording. As
shown in Figure 4C, prolonged exposure
to P7C3 repaired morphological deficits
in dendritic branching of npas3/ den-
tate gyrus granular neurons. Moreover, as
shown in Figure 4D, the electrophysiolog-
ical deficit in the dentate gyrus of NPAS3-
deficient mice was also corrected by this
treatment. The corresponding electro-
physiological deficit in the CA1 region
of the hippocampus, however, was not
affected (Figure 4D), underscoring thespecificity of P7C3 to improving function of the dentate gyrus
in npas3/ mice. It was perplexing to observe that npas3/
mice having such poorly arborized dendritic branching displayed
elevated fEPSP signatures. P7C3-induced enhancement of
granular neuron arborization could foster restoration of either
excitatory or inhibitory circuitry—or a combination of the two.
The observed data favors restoration of inhibitory circuitry, yet
further experimentation will be required to resolve this question.
To further investigate the impact of P7C3 on hippocampal
circuitry, we used immunohistochemistry to visualize the expres-
sion levels of synapsin proteins 1 and 2. Synapsins are major
phosphoproteins in synaptic vesicles that modulate neurotrans-
mitter release. Immunohistochemical staining assays revealed
P7C3-dependent normalization of synapsin 1 and 2 protein
levels in the dentate gyrus molecular layer of npas3/ mice
(Figure S3C). P7C3-mediated normalization was also observed
for synaptobrevin 2, another marker of synaptic vesicle abun-
dance (Figure S3D).
Relative to vehicle controls, prolonged P7C3 administration
did not affect the health of mothers, embryos, weanlings, or
young-adult mice. Gross histology of brain tissue was normal39–51, July 9, 2010 ª2010 Elsevier Inc. 43
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Figure 4. P7C3 Corrects Morphological and
Electrophysiological Deficits in npas3/
Dentate Gyrus
(A) Golgi-Cox staining of the dentate gyrus
revealed aberrant dendritic arborization in
npas3/ mice relative to wild-type littermates
(ten sections from each of five mice in each group).
In addition to reduced dendritic length and branch-
ing, npas3/ dentate gyrus granular neurons also
exhibited significantly reduced spine density rela-
tive to wild-type littermates (*p < 0.00001,
Student’s t test). The top lower-power micro-
graphs of dentate gyrus were taken at the same
magnification (the scale bar represents 200 mm).
For the bottom two higher-power micrographs of
dendritic spines, the scale bar represents 10 mM.
(B) In hippocampal slice preparation from
npas3/ mice, synaptic transmission, as as-
sessed by whole-field recordings of fEPSPs, was
increased both in the outer molecular layer of the
dentate gyrus and the CA1 region of the hippo-
campus relative to that of wild-type mice.
(C) Golgi-Cox staining of dentate gyrus granular
neurons showed that prolonged daily treatment
of npas3/ mice with P7C3 enhanced dendritic
arborization. Results shown are representative of
ten sections from each of five mice in each group.
Higher-power micrographs are shown on top (the
scale bar represents 25 mm), and a lower-power
micrograph illustrating the entire granular layer of
the dentate gyrus is shown below (the scale bar
represents 200 mm).
(D) Prolonged administration of P7C3 normalized
whole field recordings of fEPSPs in the dentate
gyrus but not the CA1 region of npas3/ mice.
In all graphs, data are expressed as mean ± SEM.
See also Figure S3.in both compound- and vehicle-treated animals, and there was
no evidence of neuronal cell loss or degenerative changes (cyto-
plasmic eosinophilia, vacuolization, or nuclear pyknosis). The
only morphological change, other than normalization of dendritic
arborization of dentate gyrus granular neurons, was a
compound-dependent increase in the thickness of the granular
layer itself. The thickness of the granular layer of the dentate
gyrus is roughly 40% less in npas3/ mice compared to wild-
type littermates. Prolonged administration of P7C3 significantly
corrected this deficit without affecting the thickness of other
hippocampal layers in npas3/ mice (Figure S3E).
Recognizing that reduced thickness of the npas3/ dentate
gyrus granular layer could be attributed to increased apoptosis
of proliferating neural precursor cells, we examined the effect
of P7C3 treatment on apoptosis in the hippocampus of
npas3/ mice through immunohistochemical staining of
CCSP3. After 12 days of orally delivered P7C3 (20 mg/kg) to
adult npas3/ mice, a statistically significant reduction in
CCSP3 staining was observed in the dentate gyrus (Figure 5).
We thereby propose that P7C3 facilitates repair of the granular
layer of the dentate gyrus in npas3/ mice by overcoming
a genotype-specific enhancement in apoptosis.44 Cell 142, 39–51, July 9, 2010 ª2010 Elsevier Inc.P7C3 Protects Mitochondrial Membrane Integrity
Work pioneered by the laboratory of Xiaodong Wang has shown
that an intrinsic pathway leading to apoptosis emanates from
mitochondria (Liu et al., 1996; Yang et al., 1997). Knowing that
P7C3 ameliorates the death of newborn neurons in the dentate
gyrus in living mice, we wondered whether its function might
relate to mitochondrial integrity. With the help of the Wang lab,
assays were established to test whether P7C3 might protect
cultured U2OS cells from calcium-induced mitochondrial disso-
lution (Distelmaier et al., 2008). Tetramethylrhodamine methyl
ester (TMRM) dye is sequestered by active mitochondria, and,
when loaded with TMRM, vehicle-treated cells released the
dye within 15 min of exposure to the calcium ionophore
A23187. By contrast, dye release was fully prevented in cells
exposed to as little as 10nM of P7C3 (Figure 6). The P7C3A29
and P7C3A35 variants of P7C3 known to be inactive in vivo
were also inactive in this assay. Preservation of mitochondrial
membrane potential in this assay was observed for the R-enan-
tiomer of P7C3-OMe, but not the S-enantiomer. Finally, protec-
tion of mitochondrial membrane permeability was observed at
an enhanced level for the P7C3A20 variant, which also exhibited
the highest level of proneurogenic activity (Figure 2). P7C3, but
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Figure 5. P7C3 Normalizes Elevated Levels of Hippocampal
Apoptosis in npas3/ Mice
Immunohistochemical detection of CCSP3 showed elevated apoptosis in the
dentate gyrus of npas3/ animals (*p < 0.001). This was normalized by pro-
longed treatment with P7C3. Three adult animals were tested in each group.
Data are expressed as mean ± SEM. The scale bar represents 200 mM.not the inactive P7C3A29 derivative, was also capable of
preserving mitochondrial integrity in cultured primary cortical
neurons (Figure S4).Comparison of P7C3 to Two Classes of Antiapoptotic
Compounds
We next compared P7C3 to two other classes of putatively anti-
apoptotic compounds. Serono Pharmaceuticals Research Insti-
tute reported a series of brominated carbazole compounds
capable of inhibiting Bid-mediated release of cytochrome c in
isolated mitochondria (Bombrun et al., 2003). Independent
studies from Russia also reported the discovery of a putatively
antiapoptotic chemical. In the latter case a tetrahydro-g-carbo-
line, an antihistamine trade-named Dimebon, has been reported
to block apoptosis of cortical neurons exposed to amyloid-beta
peptide (Bachurin et al., 2001) and to protect mitochondrial
membrane potential (Bachurin et al., 2003).
Chemical samples corresponding to the most active Serono
compound (Figure 7, Serono compound 1), the least active
Serono compound (Figure 7, Serono compound 2), and Dime-
bon (Figure 7) were obtained and tested for proneurogenic
activity in mice. As shown in Figure 7A, the more active of theSerono compounds exhibited proneurogenic activity superior
to its less active relative. It was likewise observed that Dimebon
was proneurogenic in vivo. Neither the active Serono compound
nor Dimebon, however, reached an equivalent ceiling of pro-
neurogenic efficacy as P7C3, and the dose required for maximal
efficacy was higher in both cases than P7C3 (Figure 7A).
In an effort to quantitatively compare the in vivo, proneuro-
genic activities of P7C3, its A20 derivative, Dimebon, and the
active Serono compound (Serono compound 1), we first sought
to define the ceiling of efficacy (CoE) for each compound. The
background level of neurogenesis in experiments conducted
on wild-type mice throughout this study was consistently
measured to be 14.5 ± 1.1 3 106 BrdU-positive neurons per
mm3 of the dentate gyrus (Figures 1 and 2 and Figure S1). Admin-
istration of P7C3 elevated the level to 30 ± 1.43 106 BrdU-posi-
tive neurons per mm3, corresponding to a 100% increase over
basal levels (Figures 2 and 7 and Figure S1). The P7C3A20
variant increased the observed CoE level to 150% (Figure 2),
whereas administration of both Dimebon and the active Serono
compound achieved CoE values corresponding to a 60%
increase in neurogenesis (Figure 7A).
To compare the relative potencies of the four chemicals,
we asked what levels of drug administration were required to
reach the 60% CoE level of Dimebon and Serono compound 1.
As shown in Figure 7B, 30 mM Dimebon, 10 mM Serono com-
pound 1, and between 1 and 3 mM P7C3 were respectively
required to reach the 60% CoE level. Moreover, as shown in
Figure 2B, administration of only 0.1 mM P7C3A20 variant
exceeded the 60% CoE level. As judged by this simplistic defini-
tion of potency, the amount of P7C3 required to achieve the 60%
CoE level was somewhere between one-tenth and one-thirtieth
the level of Dimebon (1–3 mM versus 30 mM). Finally, the A20
derivative of P7C3 exceeded the CoE of Dimebon when admin-
istered at a dose of as little as 0.1 mM, giving evidence of
estimated potency 300 times that of Dimebon. Minimally, these
interpretations suggest that further SAR assays should facilitate
the generation of pharmacophores with substantial enhance-
ment in potency and ceiling level of proneurogenic efficacy.
We next turned to the assay for calcium-induced mitochon-
drial dissolution to assess the activities of the two Serono
compounds and Dimebon. As shown in Figure 7B, Dimebon pro-
tected mitochondrial membrane integrity at the 10 mM and 1 mM
levels but not at submicromolar concentrations. Serono
compound 1 also afforded protection of mitochondrial
membrane potential, losing activity between the 100 nM and
10 nM test levels. Finally, Serono compound 2 was inactive at
all doses tested. Not only do these data parallel the proneuro-
genic activities of the three compounds in living mice
(Figure 7A), but—in the case of the two Serono compounds—
parallel the reported activities in test tube reactions measuring
protection of mitochondria from Bid-mediated cytochrome c
release (Bombrun et al., 2003).
P7C3 Ameliorates Cognitive Decline in Aged Rats
If possible, we would have performed behavioral studies of
learning and memory on npas3/ mice that had received pro-
longed treatment with either P7C3 or vehicle. Unfortunately,
npas3/ mice are incapable of swimming and thus not able toCell 142, 39–51, July 9, 2010 ª2010 Elsevier Inc. 45
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Figure 6. P7C3 and Its Analogs Preserve Mitochondrial
Membrane Potential in Parallel to Proneurogenic
Activity
U2OS cells were loaded with tetramethylrhodamine methyl
ester (TMRM) dye and then exposed to the calcium ionophore
A23187 either in the presence or absence of test compounds.
P7C3 preserved mitochondrial membrane potential following
exposure to the calcium ionophore A23187 in a dose-depen-
dent manner. The protective effect of P7C3 was enantiomeric
specific. The (R)-enantiomer of P7C3-OMe blocked dye release
at levels as low as 1 nM, whereas the (S)-enantiomer failed to
block dye release even at the highest drug dose tested
(100 nM). The more active, proneurogenic analog (P7C3A20)
exhibited dye release protection at all doses tested, yet analogs
devoid of proneurogenic activity (P7C3A29 and P7C3A35)
failed to preserve mitochondrial membrane potential at any
test dose. Each compound was evaluated in triplicate with
similar results. See also Figure S4.
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Figure 7. Comparison of P7C3 to Other Putative Antiapoptotic
Agents
(A) Adult mice (n = 4 for each group) were administered equivalent dose esca-
lations of P7C3, Dimebon, and Serono compounds 1 and 2 for 1 week. Dime-
bon was observed to enhance hippocampal neurogenesis, yet with diminished
potency and efficacy relative to P7C3. Serono compound 1, which was more
active than Serono compound 2 in inhibiting BID-mediated cytochrome c
release from isolated mitochondria (Bombrun et al., 2003), was similarly supe-
rior to Serono compound 2 in enhancing in vivo neurogenesis. The proneuro-
genic efficacy of Serono compound 1 was comparable to Dimebon and dimin-
ished relative to P7C3. Horizontal bars designate ceiling of efficacy (CoE)
levels for each compound. There is no CoE determination for Soreno
compound 2 because this agent did not significantly enhance neurogenesis.
Data are expressed as mean ± SEM.be evaluated in the standard assay for hippocampus-dependent
learning—the Morris water maze test. As such, we turned to
aged Fisher rats as a means of performing behavioral tests
capable of assessing the potential benefits of P7C3 on hippo-
campus-dependent learning. It is well established that normal
rodent aging is associated with attenuation of hippocampal neu-
rogenesis (Kuhn et al., 1996, Driscoll et al., 2006). Reduced neu-
rogenesis in aged rats is likely related to increased neuronal
apoptosis in the aged rat brain (Martin et al., 2002; Kim et al.,
2010). These changes have been hypothesized to contribute to
cognitive decline as a function of terminal aging.
We first evaluated whether P7C3 would enhance hippocampal
neurogenesis in aged rats as it does in adult mice. Rats were in-
jected with a daily, IP dose of either 10 mg/kg of P7C3 or vehicle,
coinjected with a daily dose of BrdU, and then sacrificed after
7 days for immunohistochemistry. As shown in Figure S5A,
compound-treated animals revealed a 500% increase in BrdU
labeling in the dentate gyrus relative to vehicle-treated controls.
Immunohistochemical staining with antibodies to doublecortin
likewise revealed a robust, compound-specific enrichment in
this marker of newborn neurons.
Having observed proneurogenic efficacy of P7C3 in this short-
term assay, we then tested whether prolonged administration of
P7C3 might ameliorate age-related decline in cognition by sub-
jecting 18-month-old rats to daily administration of either
10 mg/kg of P7C3 or vehicle for 2 months. Animals of both
groups were further subjected to weekly IP administration of
BrdU (50 mg/kg) for later immunohistochemical measurements
of hippocampal neurogenesis. As a control, both P7C3- and
vehicle-treated groups were confirmed to display equal ability
to physically participate in the task, and learn the task, as shown
by decreased latency times to find the hidden platform over the
5 day training period, both before and after 2 months of treat-
ment (Figure S5B). Moreover, neither swim speed (Figure S5C)
nor locomotor activity (Figure S5D) varied with age or treatment
paradigm.
After 2 months of compound or vehicle administration, cogni-
tive ability was assessed blind to treatment group by removing
the goal platform. Animals of the P7C3-treated group retained
a statistically significant improvement in ability to navigate to
the region of the missing platform, as evidenced by performance
in the probe test. As shown in Figure 8A, when the platform was
removed from the maze, rats treated with P7C3 crossed the
precise location previously containing the platform significantly
more often than vehicle-treated rats. Furthermore, P7C3-treated
rats spent a higher percentage of time in the general goal area,
defined as the quadrant previously containing the platform,
than vehicle-treated rats (35.5% ± 2.2% for P7C3 treated,
28.1% ± 2.6% for vehicle treated, Student’s t Test, p < 0.02).(B) Cultured U2OS cells were loaded with TMRM dye and exposed to a calcium
ionophore in the presence of different doses of Dimebon, Serono compound 1,
or Serono compound 2. Dimebon protected the mitochondrial membrane
potential of U2OS cells only at the relatively high doses of 10 and 1 mM. The
more active, proneurogenic Serono compound 1 showed an enhanced ability
to preserve mitochondrial membrane potential relative to the less active
Serono compound 2. Serono compound 1 lost activity between 10 and 1 nM
doses.
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Figure 8. P7C3 Enhances Hippocampal
Neurogenesis, Ameliorates Cognitive
Decline, and PreventsWeight Loss in Termi-
nally Aged Rats
(A) Prior to treatment, both groups (n = 23 for each
group) showed similar frequency of crossings
through the goal platform. After 2 months of treat-
ment, however, P7C3-treated rats displayed
a statistically significant increase of crossings
through the goal platform area relative to vehicle-
treated rats.
(B) P7C3-treated rats displayed significantly
enhanced hippocampal neurogenesis, as as-
sessed by BrdU incorporation, relative to vehicle-
treated rats. Many more of the BrdU-labeled cells
were noted to have migrated into the granular layer
in P7C3-treated rats in comparison to vehicle-
treated animals, consistent with their functional
incorporation into the dentate gyrus as properly
wired neurons. The scale bar represents 50 mM.
(C) Relative to vehicle-treated animals, P7C3-
treated rats displayed a significantly lower number
of cleaved caspase 3-positive cells in the dentate
gyrus, indicating that P7C3 was capable of inhibit-
ing apoptosis in the aged rat brain. The scale bar
represents 50 mM.
(D) Relative to vehicle-treated animals, P7C3-
treated rats were observed to maintain stable
body weight as a function of terminal aging.
In all graphs data are expressed as mean ± SEM.
See also Figure S5.After behavioral testing, animals were sacrificed for immuno-
histochemical detection of BrdU and CCSP3. As shown in
Figure 8B, the dentate gyrus of rats exposed to P7C3 showed
a 3-fold higher level of BrdU-positive neurons than that of the
vehicle group. Moreover, P7C3-treated animals showed a statis-
tically significant reduction in the number of CCSP3-positive
cells relative to vehicle controls (Figure 8C).
Unexpectedly, administration of P7C3 helped rats maintain
stable body weight with aging, in contrast to vehicle-treated
rats, whose weight declined steadily with age (Figure 8D).
P7C3-mediated effects on body weight were independent of
food intake (Figure S5E), and treatment of aged rats with P7C3
had no effect on postfasting blood glucose levels (Figure S5E).
It will be of interest to determine whether P7C3-mediated pres-
ervation of body weight in aged rats operates via central or
peripheral modes of action.
DISCUSSION
We hereby provide evidence for the discovery of a series of pro-
neurogenic, neuroprotective compounds. The aminopropyl
carbazole designated P7C3 was one of eight proneurogenic
compounds discovered in an unbiased screen of 1000 drug-
like chemicals. P7C3 is orally bioavailable, endowed with a rela-
tively long half-life, capable of crossing the blood-brain barrier,
and safely tolerated by mice exposed to the chemical throughout
late embryonic development, early postnatal development, and
the first 2 months after weaning. P7C3 protects the survival of
newborn neurons in the dentate gyrus, the majority of which nor-
mally die as they transit an arduous ‘‘differentiation gauntlet’’48 Cell 142, 39–51, July 9, 2010 ª2010 Elsevier Inc.lasting upwards of 1 month before surviving cells become func-
tionally wired into the central nervous system. Administration of
P7C3 to normal mice, as well as npas3/ mice, enhanced
survival of neurons subsequent to their birth in the SGZ.
Compound administration promoted the generation of mature
granular neurons that appeared to be normal by morphological
and electrophysiological criteria. Finally, prolonged administra-
tion of P7C3 to aged rats ameliorated age-related decline in
cognition. We hypothesize that this behavioral enhancement in
cognition may be due to P7C3-mediated improvement in the
survival of newborn hippocampal neurons.
When exposed to a calcium ionophore, the mitochondria of
cultured cells lose membrane potential and release a readily de-
tectible vital dye. Treatment of cultured cells with low nanomolar
concentrations of P7C3 blocked mitochondrial dissolution in
response to increased levels of intracellular calcium. Inactive
variants of P7C3, as assayed in living mice, were inactive in
this assay of mitochondrial membrane permeability protection.
It was likewise observed that the single SAR variant of P7C3
with enhanced potency and efficacy in the in vivo assay of neu-
rogenesis also showed superior activity in the mitochondrial
assay. Finally, the active, R-enantiomer of P7C3 was observed
to be active in the mitochondrial assay—but not the S-enan-
tiomer. We tentatively conclude that the in vivo, proneurogenic
activity of P7C3 can be attributed to its capacity to protect mito-
chondrial integrity and thereby mitigate the death of newborn
neurons between their time of birth and functional incorporation
into the granular layer of the dentate gyrus. The validity of this
conclusion will await identification of the molecular target of
the compound.
Mice tailored to either eliminate expression of the proapop-
totic Bax protein (Sun et al., 2004; Kim et al., 2009) or overex-
press the antiapoptotic Bcl-2 protein (Kuhn et al., 2005) have
been shown to over-produce newborn neurons in the dentate
gyrus of the adult brain by manipulating apoptosis. We tenta-
tively conclude that P7C3 achieves a similar functional outcome
as genetic manipulation of the pro- and antiapoptotic Bax and
Bcl2 proteins. This interpretation, in retrospect, may explain
why P7C3 was observed to enhance BrdU incorporation selec-
tively in the dentate gyrus of the adult mouse brain. If the
compound only functions to enhance the survival of newborn
neurons, and has no role in stimulating the birth of neurons, it
would be expected to enhance BrdU incorporation only in brain
regions endogenously active in neurogenesis.
Whereas we have not carefully monitored the effects of P7C3
in all regions of the rodent brain, the only other brain region
clearly and reproducibly observed to accumulate higher levels
of BrdU-positive neurons in response to administration of
P7C3 was the rostral migratory stream (RMS) (data not shown).
The RMS contains migrating neurons born in the SVZ and
destined for incorporation into the olfactory bulb. Further studies
of the effects of P7C3 on SVZ-localized neurogenesis will be
required in order to assess whether common mechanisms are
shared with what are reported herein for P7C3-mediated effects
on neurogenesis in the dentate gyrus.
If the efficacy of P7C3 can be attributed to its ability to protect
newborn neurons from apoptosis, it is perplexing that prolonged
administration of the compound throughout the third trimester of
embryonic development, all of weaning, and 2 months after
weaning—at doses considerably higher than that required for
proneurogenic efficacy—did not result in significant aberration
in mouse development. Apoptosis is vitally important for a myriad
of developmental processes. As such, it would appear that the
effects of P7C3 are somehow restricted to unique applications
of apoptosis or that the survival of newborn neurons in the den-
tate gyrus is unusually sensitive to apoptosis.
Perhaps the most surprising discovery reported herein is the
functional similarity between P7C3 and two other classes of anti-
apoptotic compounds (the Serono compounds and Dimebon),
shown in our studies to be proneurogenic. Dimebon is a tetrahy-
dro-g-carboline long deployed in Russia as an antihistamine
therapeutic. Anecdotal observations by Russian physicians
raised the possibility that Dimebon might ameliorate the symp-
toms of age related cognitive decline (O’Brien, 2008; Burns
and Jacoby, 2008), prompting an American biotechnology
company to perform Food and Drug Administration-sanctioned
clinical trials on patients suffering from various forms of neurode-
generative disease. As reported in the Lancet in 2008, prolonged
treatment of Alzheimer’s patients with Dimebon substantially
improved symptoms (Doody et al., 2008). Disconcertingly,
unpublished reports coming from a larger, phase 3 clinical trial
failed to provide evidence of any difference in disease progres-
sion between Dimebon- and placebo-treated patients (Miller,
2010).
The results of this study raise the possibility that Dimebon,
P7C3, and the Serono compounds may operate via a common
mechanistic pathway. If correct, this conclusion almost certainly
rules out the possibility that the clinical utility of Dimebon asa therapeutic treatment for age-related decline in cognition can
be attributed to its antihistamine activity. Highly effective pro-
neurogenic derivatives of P7C3 have been found to retain no
detectable inhibitory activity to any of the known histamine
receptors (McKnight et al., 2010, patent pending). The specula-
tive idea that these chemicals share a common mode of action
will only be rigorously tested upon identification of their molec-
ular target(s). For the sake of patients suffering from Alzheimer’s
disease, it is hoped that the apparently marginal clinical utility of
Dimebon might be enhanced by improvements in both its
potency and ceiling of proneurogenic, neuroprotective efficacy.
If so, our work offers concrete assays for the development of
improved versions of these neuroprotective drugs.EXPERIMENTAL PROCEDURES
Approval for the animal experiments described herein was obtained by the
University of Texas Southwestern Medical Center Institutional Animal Care
and Use Committee. Extended Experimental Procedures are available online.
Immunohistochemistry
Standard procedures were employed for staining paraformaldehyde-perfused
brain tissue with the antibodies against the following antigens: BrdU (1:100,
Roche), CCSP3 (1:200, Cell Signaling), synapsin 1/2 (1:250, Synaptic
Systems), synaptobrevin 2 (1:500, Synaptic Systems), Prox1 (1:1000, Chemi-
con), NeuN (1:1000, Millipore), GFAP (1:2000, Millipore), S100b (1:2000,
Sigma), GSTpi (1:3000, BD Biosciences), and PDGFa (1:500, BD PharMingen).
Statistics
All p values were obtained with the Student’s t test.
Electrophysiology
Hippocampal slices were maintained at 30C and perfused continuously with
aCSF in the recording chamber. In the dentate gyrus, stimulating and
recording electrodes were positioned in the outer molecular layer, which is
innervated by axons of the perforant pathway from the entorhinal cortex. In
CA1, stimulation and recording electrodes were positioned in the stratum ra-
diatum, which is innervated by the Schaffer collateral axons from CA3. Stim-
ulus intensity was increased in 5 mA increments, the slope of the decreasing
part of field potentials was measured, and fEPSP was quantified relative to
the amplitude of the fiber volley, which represents firing of action potentials
in presynaptic axons. For input-output measurements, stimulus intensity
was increased in 5 mA increments up to 100 mA. FPs were filtered at 2 kHz,
acquired, and digitized at 10 kHz on a computer with customized LabVIEW
software (National Instruments, Austin, TX). The 20/80 slope of the FP was
used in this experiment.
Golgi-Cox Staining
Golgi-Cox staining was accomplished with the rapid Golgi stain kit (FD Neuro-
Techonologies, PK-401). Tissue was analyzed with an Olympus BX51 micro-
scope and Neurolucida software (MBF Biotechnology).
Mitochondrial Dissolution Assay
Live-cell imaging of mitochondrial integrity was executed according to estab-
lished methods (Distelmaier et al., 2008) in U20S cells and primary cortical
neurons from E17 rats.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, one table, and chemical synthesis and can be found with this article
online at doi:10.1016/j.cell.2010.06.018.Cell 142, 39–51, July 9, 2010 ª2010 Elsevier Inc. 49
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